Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ALL: a Children's Oncology Group (COG) study-Reference-Cited by-同舟云学术

Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ALL: a Children's Oncology Group (COG) study

Published:2012-02-02 Issue:4 Volume:157 Page:507-510
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Chang Bill H.¹,Willis Stephanie G.²,Stork Linda¹,Hunger Stephen P.³,Carroll William L.⁴,Camitta Bruce M.⁵,Winick Naomi J.⁶,Druker Brian J.,Schultz Kirk R.⁷

Affiliation:

1. Division of Pediatric Hematology and Oncology; Department of Pediatrics and OHSU Knight Cancer Institute; Oregon Health & Science University; Portland; OR; USA

2. Division of Hematology and Medical Oncology; OHSU Knight Cancer Institute; Oregon Health & Science University; Portland; OR; USA

3. Division of Pediatric Hematology, Oncology; BMT; Children's Hospital Colorado; University of Colorado School of Medicine; Aurora; CO; USA

4. NYU Cancer Institute; New York University Medical Center; New York; NY; USA

5. Midwest Center for Cancer and Blood Disorders; Children's Hospital and the Medical College of Wisconsin; Milwaukee; WI; USA

6. Department of Pediatric Hematology/Oncology; University of Texas Southwestern Medical Center; Dallas; TX; USA

7. Pediatric Hematology/Oncology/BMT; University of British Columbia and BC Children's Hospital; Vancouver; BC; Canada

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2012.09039.x/fullpdf

Reference9 articles.

1. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005;Arico;Journal of Clinical Oncology,2010

2. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia;Boulos;Blood,2011

3. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome;Druker;The New England Journal of Medicine,2001

4. Requirement of Src kinases Lyn, Hck, and Fgr for BCR-ABL 1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia;Hu;Nature Genetics,2004

5. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors;Jones;Cancer,2008

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells;Leukemia;2024-06-21

2. Tyrosine kinase inhibitor resistance in de novo BCR::ABL1–positive BCP-ALL beyond kinase domain mutations;Blood Advances;2024-04-10

3. A systematic analysis of the landscape of synthetic lethality-driven precision oncology;Med;2024-01

4. Philadelphia Chromosome Positive and Philadelphia-Like Acute Lymphoblastic Leukemia in Children and Adolescents: Current Management, Controversies and Emerging Concepts;Indian Journal of Pediatrics;2023-08-26

5. Molecular Characteristics and Clinical Significance of Acute B-Cell Acute Lymphoblastic Leukemia in Children;Advances in Clinical Medicine;2023